share_log

HIVE Blockchain Techs Analyst Ratings

HIVE Blockchain Techsのアナリスト評価

Benzinga Analyst Ratings ·  2022/08/18 06:36
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/18/2022 12.72% HC Wainwright & Co. $6 → $7 Maintains Buy
08/04/2022 -3.38% HC Wainwright & Co. $5 → $6 Maintains Buy
03/25/2022 -54.91% Canaccord Genuity → $2.8 Initiates Coverage On → Buy
06/27/2019 Craig-Hallum Downgrades Buy → Hold

HIVE Blockchain Techs Questions & Answers

What is the target price for HIVE Blockchain Techs (HIVE)?

The latest price target for HIVE Blockchain Techs (NASDAQ: HIVE) was reported by HC Wainwright & Co. on August 18, 2022. The analyst firm set a price target for $7.00 expecting HIVE to rise to within 12 months (a possible 12.72% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for HIVE Blockchain Techs (HIVE)?

The latest analyst rating for HIVE Blockchain Techs (NASDAQ: HIVE) was provided by HC Wainwright & Co., and HIVE Blockchain Techs maintained their buy rating.

When is the next analyst rating going to be posted or updated for HIVE Blockchain Techs (HIVE)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HIVE Blockchain Techs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HIVE Blockchain Techs was filed on August 18, 2022 so you should expect the next rating to be made available sometime around August 18, 2023.

Is the Analyst Rating HIVE Blockchain Techs (HIVE) correct?

While ratings are subjective and will change, the latest HIVE Blockchain Techs (HIVE) rating was a maintained with a price target of $6.00 to $7.00. The current price HIVE Blockchain Techs (HIVE) is trading at is $6.21, which is within the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする